Compare IQV & GFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IQV | GFS |
|---|---|---|
| Founded | 1982 | 2009 |
| Country | United States | United States |
| Employees | 93000 | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1B | 37.8B |
| IPO Year | 2013 | 2017 |
| Metric | IQV | GFS |
|---|---|---|
| Price | $238.70 | $53.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 12 |
| Target Price | ★ $227.13 | $45.08 |
| AVG Volume (30 Days) | 1.4M | ★ 4.0M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 4.67 | N/A |
| EPS | ★ 1.61 | N/A |
| Revenue | ★ $9,739,000,000.00 | N/A |
| Revenue This Year | $6.77 | $7.64 |
| Revenue Next Year | $5.89 | $9.90 |
| P/E Ratio | $144.37 | ★ $29.28 |
| Revenue Growth | ★ 41.60 | N/A |
| 52 Week Low | $154.50 | $31.51 |
| 52 Week High | $251.36 | $92.55 |
| Indicator | IQV | GFS |
|---|---|---|
| Relative Strength Index (RSI) | 62.34 | 33.24 |
| Support Level | $218.57 | $45.80 |
| Resistance Level | $247.52 | $90.61 |
| Average True Range (ATR) | 7.83 | 2.95 |
| MACD | 0.63 | 0.15 |
| Stochastic Oscillator | 64.79 | 24.11 |
Iqvia is a global leader in clinical research and technology solutions for the life science industry. Formed in 2016 from the merger of Quintiles and IMS Health, it combined clinical trial services with extensive healthcare data and analytics. Its research and development solutions segment provides outsourced clinical development services spanning drug discovery, trial design, patient recruitment, site management, clinical testing, real-world studies, and the regulatory approval process. Its commercial solutions segment helps companies optimize product commercialization through analytics, technology, and outsourced sales and medical services. Together, Iqvia supports customers across the life science industry, and it serves biopharmaceutical firms, providers, payers, and policymakers.
GlobalFoundries is a top-five contract semiconductor manufacturer globally. It was originally the manufacturing arm of Advanced Micro Devices before it was spun out in 2009. The foundry sells chips into a range of end markets including smartphones, PCs, Internet of Things, data centers, automotive, industrial, and so on, but primarily focuses on more mature process technologies. Until 2021, the firm was privately held by Mubadala Investment, the sovereign wealth fund of the United Arab Emirates, which remains its controlling shareholder today. GlobalFoundries merged with Chartered Semiconductor Manufacturing in 2009 and acquired IBM's chipmaking business in 2015. GF is headquartered in Malta, New York, and has about 13,000 staff.